Verve Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Verve Therapeutics's estimated annual revenue is currently $23.9M per year.
- Verve Therapeutics's estimated revenue per employee is $71,898
- Verve Therapeutics's total funding is $216M.
- Verve Therapeutics's current valuation is $1.6B. (January 2022)
Employee Data
- Verve Therapeutics has 332 Employees.
- Verve Therapeutics grew their employee count by 7% last year.
Verve Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and Strategic Advisor | Reveal Email/Phone |
2 | Co-Founder and Senior Scientific Advisor | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | SVP, Legal Affairs & Chief IP Counsel | Reveal Email/Phone |
5 | CEO, Founder | Reveal Email/Phone |
6 | Chief Staff | Reveal Email/Phone |
7 | Chief Medical Officer | Reveal Email/Phone |
8 | VP, Program and Alliance Management | Reveal Email/Phone |
9 | SVP, Corporate Strategy & Partnerships | Reveal Email/Phone |
10 | SVP Research and Early Development | Reveal Email/Phone |
Verve Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Verve Therapeutics?
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. The company brings together human genetics analysis and gene editing ￃﾢ￢ﾂﾬ￢ﾀﾜ two of the biggest breakthroughs in 21st century biomedicine ￃﾢ￢ﾂﾬ￢ﾀﾜ to develop transformative therapies for coronary heart disease. Verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, Biomatics Capital, Wellington Management, Casdin Capital, and Partners Innovation Fund. The company was recognized as a "2020 Best Places to Work" by the Boston Business Journal. Verve is headquartered in Cambridge, Massachusetts.
keywords:N/A
$216M
Total Funding
332
Number of Employees
$23.9M
Revenue (est)
7%
Employee Growth %
$1.6B
Valuation
N/A
Accelerator
Verve Therapeutics News
Verve Therapeutics (NASDAQ:VERV) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 22nd, 2022.
Verve Therapeutics is a biotechnology company with a vision to provide cutting-edge solutions to cardiovascular diseases.
Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential...
VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3 Program Highlight Potent Editing with Proprietary GalNAc-LNP Delivery in a Novel NHP Model of Homo ...
Verve Therapeutics — a biotech company pioneering gene-editing medicines to treat cardiovascular disease — recently announced it has raised $94 million in Series B funding. These are the details. Verve Therapeutics — a biotech company pioneering gene-editing medicines to treat cardiovascular di ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $87.7M | 334 | 2% | N/A |
#2 | $72.5M | 334 | 48% | $420M |
#3 | $53.3M | 336 | 7% | $134.8M |
#4 | $42.8M | 336 | 0% | N/A |
#5 | $323.6M | 338 | -6% | $1.2B |